There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aeterna Zentaris (AEZS – Research Report) and Portage Biotech Inc (PRTG – Research Report) with bullish sentiments.
Aeterna Zentaris (AEZS)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aeterna Zentaris today and set a price target of $1.50. The company’s shares closed last Thursday at $0.21, close to its 52-week low of $0.16.
According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Aeterna Zentaris is a Moderate Buy with an average price target of $1.50.
See today’s best-performing stocks on TipRanks >>
Portage Biotech Inc (PRTG)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Portage Biotech Inc, with a price target of $32.00. The company’s shares closed last Thursday at $7.61, close to its 52-week low of $4.62.
According to TipRanks.com, Burns is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Portage Biotech Inc with a $32.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AEZS:
- H.C. Wainwright Thinks NextPlay Technologies’ Stock is Going to Recover
- H.C. Wainwright Thinks Golden Minerals Co’s Stock is Going to Recover
- Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), RVL Pharmaceuticals (RVLP)
- Amazon’s Newark Air Cargo Expansion Plan Fails to Takeoff
- Aurora Mobile’s Subsidiary SendCloud Partners with Ding Xiang Yuan to Jointly Enhance Customer Reach
